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The skin represents an important interface be-
tween the external environment and the inter-
nal tissues, and one of its major roles is to 
provide immune function at this critical site 
(1). The most superfi  cial layer of the skin, the 
epidermis, provides the fi  rst immune barrier 
against foreign invasion. The dermis, separated 
from the epidermis by the basement mem-
brane, supports the vascular network that sup-
plies the avascular epidermis with nutrients (1). 
Immune cells are distributed on both sides of 
the basement membrane and participate in the 
defense against pathogens through professional 
antigen-presenting cells. These include DCs in 
the epidermis (2), also called Langerhans cells 
(LCs), and DCs in the dermis (3–5). Dermal 
immune cells include dermal DCs, macro-
phages, mast cells, and T lymphocytes. Rare B 
lymphocytes and NK cells can also be found 
in the dermis, whereas plasmacytoid DCs and 
neutrophils are rarely present in the absence of 
cutaneous infl  ammatory reactions (6–8).
Dermal DCs can be distinguished from LCs 
by the absence of Langerin expression (4–7, 9) 
and from macrophages by their expression of 
MHC class II, CD11c, and CD205, and ab-
sence or poor expression of mMGL and cyto-
plasmic phagolysosomes. LCs and dermal DCs 
are both well equipped to capture environ-
mental antigens, migrate to the draining lymph 
nodes, and initiate specifi  c T cell immune re-
sponses playing a critical role in skin immunity 
(1, 10, 11). Because of their accessibility, LCs 
have been the most extensively studied DC 
population in the skin. In contrast, dermal DCs 
are more diffi   cult to isolate and have been of-
ten overlooked in studies of skin immunity.
Recent studies demonstrating the critical 
role of dermal DCs in cutaneous immune re-
sponses have revived the interest in these cells. 
Indeed, two elegant murine models of induc-
ible in vivo LC ablation showed that contact 
hypersensitivity can occur in the absence of 
LCs (12, 13). These results are consistent with 
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previous results showing that contact hypersensitivity can de-
velop in mice in the absence of the epidermis but is abolished 
if both the epidermis and the dermis are absent (14). Another 
recent study (15) using a constitutive in vivo LC ablation 
strategy found that contact hypersensitivity is amplifi  ed in the 
absence of LCs, further emphasizing the importance of der-
mal DCs in cutaneous immune responses. Consistent with 
these data, earlier studies on cutaneous DC turnover have 
previously noted that the considerable fl  ux of DCs observed 
in skin-aff   erent lymphatics (16) contrasts with the slower 
turnover of epidermal LCs (17–19), suggesting that the ma-
jority of cutaneous DCs en route to the lymph nodes may not 
derive from epidermal LCs, but rather from the dermal DC 
population. Furthermore, recent studies using specifi  c dyes to 
follow cutaneous DC migration to the draining lymph nodes 
after sensitization of the skin have revealed that dermal DCs 
leave the skin before LCs and segregate in separate areas of 
the draining lymph nodes (13). Collectively, these results em-
phasize the critical role of dermal DCs in cutaneous immu-
nity and suggest the need for a better understanding and 
analysis of this cell population. We recently discovered that 
LCs are maintained by local radio-resistant precursors under 
steady-state conditions and are replaced by circulating precur-
sors only during major skin injuries (19). In contrast, intersti-
tial DCs present in peripheral nonlymphoid and vascularized 
tissues, such as kidney and liver (19), derived mostly from ra-
dio-sensitive precursors. We also demonstrated that recruit-
ment of circulating BM-derived LC precursors during skin 
injury is a regulated process that depends on a cascade of in-
fl  ammatory chemokines (19).
Regulation of DC homeostasis through local radio-
  resistant precursors has important implications in allogeneic 
Figure 1.  Phenotype of murine dermal DCs. (A) A dermal cell sus-
pension from naive C57BL/6 mice was stained with anti-CD45, CD11c, 
CD11b, and langerin mAbs and analyzed by fl  ow cytometry. Dot plots 
show the percentage of dermal CD45+ cells positive for CD11c and 
CD11b, whereas the overlaid histogram demonstrates that only 10% of 
dermal CD45+ CD11c+ cells express langerin, likely corresponding to 
migrating LCs. (B and C) Back skin cross sections isolated from trans-
genic C57BL/6 mice expressing an enhanced yellow fl  uorescence protein 
reporter under the control of the CD11c promoter were stained with 
anti-langerin mAb. Nuclei were counterstained with DAPI. Image of Cy3 
(langerin, red), YFP (CD11c, green), and DAPI (blue) channels show 
CD11c+ langerin– dermal DCs (arrows) and CD11c+ langerin+ LCs (aster-
isks). Bars, 10 μm. (D) Dermal cell suspensions were prepared as in A. 
Overlaid histograms show expression levels of I-Ab, CD40, CD86, CD54, 
F4/80, DEC-205, and DC-SIGN by CD45+ CD11c+ (solid line) and CD45+ 
CD11c− CD11b+ (dotted line) dermal cell subsets.JEM VOL. 203, November 27, 2006  2629
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hematopoietic cell transplantation (allo-HCT). Indeed, we 
and others have shown that the elimination of residual host 
DCs before donor T cell injection improves graft-versus-
host disease (GVHD) and survival of recipient mice after al-
logeneic BM transplant (20–26). Our fi  nding that epidermal 
LCs survive lethal doses of irradiation (24) suggests that 
conditioning regimens containing a radiation component 
may not be suffi   cient to eliminate host tissue DCs, and that 
novel therapies may be required to reduce residual alloge-
neic stimuli and improve GVHD outcome.
Skin, gut, and liver are the main tissues targeted by 
GVHD, with the skin being the most frequently aff  ected or-
gan (27). The recent emphasis on the critical role of dermal 
DCs in skin immunity suggests that in addition to LCs, der-
mal DC homeostasis can also aff   ect cutaneous GVHD in 
clinical transplantation.
RESULTS
Characterization of murine dermal DCs
In this study, we used the hematopoietic marker CD45 and 
the integrin molecules CD11c and CD11b to identify der-
mal antigen-presenting cells in mice. In total dermal cell sus-
pension, CD45+ hematopoietic cells could be divided into 
two populations based on CD11c and CD11b expression. 
These include CD11c+ and CD11c– CD11b+ cells (Fig. 1 A). 
The majority of CD45+ CD11c+ dermal cells was positive 
for CD11b and F4/80 (Fig. 1, A and D) and displayed phe-
notypic and morphological DC features (Fig. 1). In particu-
lar, CD11c+ cells expressed high levels MHC class II and 
were positive for CD205, CD86, and CD40 (Fig. 1 D), but 
negative for CD4, CD8, and B220 (not depicted). Consis-
tent with previous studies (7), few dermal CD11c+ cells 
were positive for mMGL and a small fraction (10%) of 
CD11c+ CD11b+ dermal cells expressed the LC-specifi  c 
marker langerin (9), likely corresponding to migrating LCs 
en route to draining lymph nodes (Fig. 1, B and C). Unlike 
human dermal DCs (8), murine CD11c+ cells did not ex-
press the murine analogue of human DC-SIGN (28), nor did 
any other murine dermal hematopoietic cell (Fig. 1 D). In 
contrast to CD11c+ dermal cells, CD11c– CD11b+ dermal 
cells were negative for CD205, expressed lower levels of 
MHC class II and costimulatory molecules, and were posi-
tive for F4/80 and mMGL. This subset most likely repre-
sents dermal macrophages (Fig. 1 D). Therefore, dermal 
CD45+ CD11c+ langerin– cells will be referred to as dermal 
DCs, whereas dermal CD45+ CD11c− CD11b+ cells will be 
referred to as dermal macrophages.
Turnover of dermal DCs under steady-state conditions
To explore the turnover of dermal DCs under steady-state 
conditions, we used parabiotic mice in which WT C57BL/6 
mice were paired with GFP transgenic C57BL/6 mice so 
that they shared a single blood circulation but separate or-
gans for prolonged periods of time. In these mice, GFP ex-
pression was used to trace the origin of the cells in each 
recipient. Each parabiont had complete mixing of GFP+ and 
GFP– leukocytes in the blood at the time of analysis (Fig. 2, 
A and B). In the skin of parabiotic mice, the mixing of 
  macrophages was almost complete (45% donor cells) at 6 mo 
  after parabiosis (Fig. 2, A and B). In contrast, dermal DCs 
failed to equilibrate in parabiotic partners up to 6 mo after 
parabiosis, with 80% of dermal DCs remaining of host origin 
in each partner (Fig. 2, A and B). These results suggest that, 
in contrast to dermal macrophages, a large subset of dermal 
DCs in quiescent skin is maintained independently of circu-
lating precursors.
Dermal DCs proliferate locally in quiescent skin
To examine if dermal DC homeostasis relies on proliferative 
precursors in the skin, we searched for cycling dermal DCs in 
quiescent dermis. To detect these cells, we used the expres-
sion of Ki-67 antigen, a nuclear protein with a half-life of 
Figure 2.  Homeostasis of dermal DCs in quiescent skin. 
(A and B) Dermal DC turnover in parabiotic mice. Each parabiotic pair 
consisted of one WT and one GFP+ transgenic mouse (both on a C57BL/6 
background) sharing the same blood circulation. Chimerism of blood 
leukocytes and dermal DCs was analyzed at 6 mo after initiation of para-
biosis. Bar graphs show the percentage of GFP+ (black bars) and GFP– 
(white bars) cells among CD45+ langerin– CD11c+ dermal DCs, CD45+ 
langerin– CD11c– CD11b+ dermal macrophages, and total blood leuko-
cytes in the GFP– (A) and GFP+ (B) partner. One representative experi-
ment out of two is shown. (C) A proportion of dermal DCs renews locally 
in quiescent skin. Back skin cross sections isolated from naive C57BL/6 
mice were stained with a mAb against CD11c and the cell cycle protein 
Ki-67 and counterstained with DAPI. Overlaid images of Cy2 (CD11c, 
green), Cy3 (Ki-67, red), and DAPI (blue) channels are displayed and show 
that dermal CD11c+ cells coexpress the cell cycle protein Ki-67 in the 
dermis. Bars, 10 μm. Bar graph shows the percentage of Ki-67+ cells 
among total dermal DCs in three separate animals. An average of 
150 dermal DCs was analyzed in each skin sample. 2630  TURNOVER OF DERMAL DENDRITIC CELLS IN MICE AND MEN | Bogunovic et al.
60–90 min (29) expressed in late G1 and maintained through 
the S, G2, and M phase of the cell cycle (29–31). Thus, Ki-
67 expression by dermal DCs should refl  ect an active prolif-
eration state. As shown in Fig. 2 C, up to 5% of CD11c+ 
dermal DCs expressed Ki-67, whereas Ki-67+ langerin+ LCs 
were present exclusively in the epidermis (not depicted). 
These data suggest that local dermal DC proliferation plays an 
important role in dermal DC homeostasis in the steady state.
Turnover of dermal DCs after congenic BM transplantation
The results above demonstrate that in the absence of skin 
  injury, interstitial dermal DCs are maintained through local 
proliferation with some participation of blood-derived pre-
cursors. Although blood-derived circulating precursors are 
likely to be sensitive to irradiation, we sought to explore 
the eff  ect of a lethal conditioning regimen on local der      mal 
DC proliferation. We reconstituted lethally irradiated 
CD45.2+ C57BL/6 mice with BM cells isolated from con-
genic CD45.1+ C57BL/6 donor mice and used expression of 
CD45 alleles to trace the origin of dermal DCs. 1 yr after re-
constitution, 25% of total dermal DCs remained of host ori-
gin, whereas the majority of dermal macrophages was replaced 
by donor cells between 1 and 3 mo (Fig. 3, A and B), suggest-
ing that a subset of dermal DCs is maintained by local radio-
resistant precursors. To examine whether residual host dermal 
DCs corresponded to postmitotic long-lived cells or rather 
were actively proliferating in situ, we tested their ability to 
  incorporate BrdU locally. We administered BrdU to lethally 
irradiated mice, which were reconstituted with congenic 
CD45.1+ BM cells 8 wk earlier, and followed BrdU incorpo-
ration in residual host (CD45.2+) dermal DCs and donor 
(CD45.1+) dermal DCs. As shown in Fig. 3 C, 3 wk after 
BrdU administration, 30% of residual host CD45.2+ dermal 
DCs incorporated BrdU in chimeric animals. At the time of 
BrdU administration, all mice had reached full donor (CD45.1) 
BM and blood chimerism; therefore, BrdU labeling of resid-
ual CD45.2+ dermal DCs must have been occurring in the 
skin. Because BrdU incorporation in the DNA occurs only in 
S phase, these results establish that a subset of dermal DCs 
derives from local radio-resistant proliferative cells.
Homeostasis of dermal DCs in infl  amed skin
To examine the fate of radio-resistant skin-derived dermal DCs 
in response to a skin injury, we reconstituted lethally irradiated 
CD45.2+ mice with CD45.1+ BM and followed the turnover 
of skin-derived (CD45.2+) dermal DCs after cutaneous expo-
sure to UV light. 4 d after exposure to UV light, we observed a 
thickening of the epidermis accompanied with a massive dermal 
leukocyte infi  ltration (Fig. 4 A) and secretion of infl  ammatory 
chemokines, including CCL-2 (Fig. 4 B) and CCL-7 (not 
depicted). These infl  ammatory changes correlated with a strong 
reduction of CD45.2+ dermal DCs and their replacement by 
donor-derived CD45.1+ dermal DCs (Fig. 4, C and D), sug-
gesting that cutaneous infl  ammation leads to elimination of local 
dermal DCs and their replacement by blood-derived dermal 
DC precursors.
Repopulation of dermal DCs in infl  amed skin requires CCR2, 
but not CCR6
Numerous chemokines are secreted in infl  amed skin, includ-
ing RANTES (a ligand for CCR1 and CCR5; reference 32); 
MCP-1/CCL2 (a ligand for CCR2; reference 33); MDC/
CCL22 and TARC/CCL17 (ligands for CCR4; references 
34 and 35); MIG/CCL9, IP10/CCL10, and ITAC/CCL11 
(ligands for CXCR3; references 36 and 37); and MIP-3α/
CCL20 (the ligand for CCR6; references 38 and 39). In ad-
dition, several chemokines are made constitutively in normal 
skin, including SDF1/CXCL12 (40), CTACK/CCL27 (41), 
and BRAK/CXCL14 (42). Among these chemokines, we 
have previously found that CCR2 and CCR6 ligands were 
critical for LC repopulation in infl  amed skin (19, 24). To ex-
plore whether CCR2 and CCR6 were also playing a role in 
the recruitment of dermal DCs to injured skin, we reconsti-
tuted lethally irradiated CD45.1+ C57BL/6 mice with a 1:1 
Figure 3.  Homeostasis of dermal DCs after BM transplantation. 
(A and B) Dermal DC chimerism after congenic BM transplantation. 
Lethally irradiated 8-wk-old CD45.2+ C57BL/6 mice were reconstituted i.v. 
with BM cells isolated from congenic CD45.1+ C57BL/6 donor mice. 
  Dermal cell suspensions were isolated at different time points after trans-
plantation and stained with anti-CD45.1, CD45.2, CD11c, CD11b, and lan-
gerin antibodies. (A) Dot plot and histogram show the percentage host 
(CD45.2+) dermal DCs among total CD11c+ langerin– dermal DCs. (B) Bar 
graphs show the percentage of host CD45.2+ dermal CD11c+ (black bars) 
and CD11c– CD11b+ (white bars) cells in the dermis of chimeric mice at 1, 
3, and 13 mo after BM transplantation. Results represent the mean of 
four independent experiments. (C) Residual host dermal DCs renew in the 
skin after BM transplantation. CD45.2+ mice were lethally irradiated and 
reconstituted with CD45.1+ BM cells. 6 wk after BM transplantation, chi-
meric mice received BrdU in their drinking water for 3 wk. Graphs show 
the percentage BrdU+ cells among gated donor CD45.1+ CD11c+ and 
host CD45.2+ CD11c+ cells in chimeric animals at different time points 
after BrdU administration. Each data point summarizes the results of 
three independent experiments.JEM VOL. 203, November 27, 2006  2631
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mixture of WT CD45.1+ BM and CD45.2+ BM cells that 
either lacked CCR2 (CCR2−/−), CCR6 (CCR6−/−), or 
both CCR2 and CCR6 (CCR2/6−/−). 1 mo after reconsti-
tution, we found that CCR2−/−, CCR6−/−, and CCR2/6−/− 
CD45.2+ and WT CD45.1+ BM gave rise to similar num-
bers of circulating B cells and neutrophils, suggesting that the 
absence of CCR2 and CCR6 did not aff  ect BM engraftment 
(not depicted). In contrast, CCR2−/− and CCR2/6−/− 
CD45.2+ CD115+ circulating monocytes represented 30–
50% of circulating CD45.2+ CCR6−/− or CD45.1+ WT 
monocytes (not depicted), confi  rming that the absence of 
CCR2 expression on hematopoietic progenitors aff  ects 
monocyte repopulation in the blood (19, 24, 43). 1 mo after 
BM reconstitution, we exposed chimeric mice to UV light 
and followed the recruitment of mutant (CD45.2+) and WT 
(CD45.1+) dermal DCs to infl  amed skin. 2 wk after exposure 
to UV light, CCR2−/− and CCR2/6−/− dermal DCs failed 
to repopulate infl  amed skin (Fig. 5 A), whereas CCR6−/− 
dermal DCs were not aff  ected (Fig. 5 A). In contrast, both 
CCR2 and CCR6 were critical for the recruitment of circu-
lating LC precursors, as described previously (Fig. 5 B; 
references 19 and 44). These diff  erences remained unchanged 
for at least 16 wk after UV light exposure (not depicted), 
establishing the essential role of CCR2 for the recruitment of 
dermal and epidermal DCs to infl  amed skin, whereas the role 
of CCR6 seems to be restricted to the repopulation of 
  epidermal LCs.
Human dermal DCs proliferate in situ under 
steady-state conditions
To determine whether human and murine dermal DC ho-
meostasis are similarly regulated, we fi  rst sought to explore 
whether dermal DCs proliferate locally in human quiescent 
skin. In humans, dermal DCs are distinguished from LCs 
based on their expression of Factor XIIIa and DC-SIGN (1, 
3). To measure local proliferation of dermal DCs in human 
skin, we costained paraffi   n-embedded skin sections, isolated 
from normal cadavers, with Factor XIIIa mAb to identify 
dermal DCs together with mAb to the cell cycle protein Ki-
67. We chose to use Factor XIIIa mAb to detect dermal DCs 
because its staining intensity on paraffi   n sections was much 
brighter than that obtained with DC-SIGN mAb. We calcu-
lated the percentage of total Factor XIIIa+ dermal DCs coex-
pressing Ki-67 antigens and established that 2–3.5% of dermal 
DCs were actively cycling in situ (Fig. 6, A and B). These re-
sults are consistent with our data in murine skin (Fig. 2 C).
Figure 4.  Homeostasis of dermal DCs in infl  amed skin. 
(A and B) UV-induced infl  ammatory changes in the skin. Backs of C57BL/6 
mice were shaved (1cm2) and exposed to UV light. 4 d later, mice were killed 
to isolate the shaved back skin. (A) Hematoxylin and eosin–stained skin 
cross sections show large infl  ammatory infi  ltrates in mice exposed to UV 
light 4 d earlier (bottom) compared with unexposed skin (top). Bars, 100 μm. 
(B) Back skin cross sections (shown in A) were stained with anti-CCL2 mAb. 
Nuclei were counterstained with DAPI. Overlaid image of Cy3 (CCL2, red) 
and DAPI (blue) channels is displayed. Bars, 10 μm. (C and D) Exposure to 
UV light eliminates skin-resident dermal DCs. C57BL/6 CD45.2+ mice were 
lethally irradiated and reconstituted with CD45.1+ BM. 1 mo after BM 
transplantation, mice were exposed to UV light or left untreated. (C and D) 
Dot plots (C) and bar graph (D) show the percentage of host (CD45.2+) or 
donor (CD45.1+) cells among total CD11c+ dermal DCs in control animals 
or 6 wk after exposure to UV light. One representative experiment out of 
fi  ve is shown in C. In D, each bar is the result of fi  ve independent experiments.
Figure 5.  Repopulation of dermal DCs in infl  amed skin depends on 
CCR2, but not CCR6. C57BL/6 CD45.1+ mice were lethally irradiated and 
reconstituted with a 1:1 mixture of CD45.1+ WT BM and CD45.2+ BM 
cells isolated from WT animals or animals lacking CCR2 (CCR2−/−), CCR6 
(CCR6−/−), or both CCR2 and CCR6 (CCR2/6−/−) as described in Materials 
and methods. 1 mo after BM transplantation, chimeric mice were exposed 
to UV light. Bar graphs show the percentage of WT CD45.1+ (white bars) 
and WT, CCR2−/−, CCR6−/−, or CCR2/CCR6−/− CD45.2+ cells (black bars) 
among total CD11c+ dermal DCs (A) and epidermal MHC class II+ LCs (B) 
3 wk after UV exposure. Each bar summarizes the results of three inde-
pendent experiments. (A) *, P = 0.0009; **, P = 0.009; (B) *, P = 0.00001; 
**, P = 0.0002; ***, P = 0.00007.2632  TURNOVER OF DERMAL DENDRITIC CELLS IN MICE AND MEN | Bogunovic et al.
Homeostasis of human dermal DCs after allo-HCT
The results above established that a subset of dermal DCs 
persists in recipient mice for >1 yr despite radiation-condi-
tioning regimen and BM transplantation. Because residual 
host DCs have been shown to be key initiators of tissue 
GVHD (20–26) after allo-HCT in mice, persistence of resid-
ual host dermal DCs in patients after allo-HCT may have 
a critical impact in clinical transplantation. Therefore, we 
sought to examine if host dermal DCs can also resist trans-
plant-conditioning regimen and persist in the skin despite 
complete donor BM chimerism in patients who receive allo-
HCT. We chose to analyze only patients who achieved com-
plete donor BM and peripheral blood leukocyte chimerism, 
and focused on time points that preceded the occurrence 
of GVHD because cutaneous GVHD leads to infl  ammatory 
changes that could aff  ect dermal DC chimerism. We ana-
lyzed only patients who received sex-mismatched allo-HCT 
and used a dual labeling technique associating fl  uorescence 
in situ hybridization (FISH) of X and Y chromosomes and 
immunostaining of dermal DCs to determine the origin 
(host vs. donor) of dermal DCs (Fig. 7 A). Dermal DCs were 
identifi  ed as HLA-DR+ langerin– cells because Factor XIIIa 
and DC-SIGN antigens were inactivated after FISH and 
Figure 6.  Human dermal DCs proliferate in situ. Cross sections of 
paraffi  n-embedded normal human skin obtained from cadavers were 
stained with anti–Factor XIIIa and anti–Ki-67 mAbs as described in Mate-
rials and methods. Nuclei were counterstained with DAPI. (A) Overlaid 
images of Cy2 (Factor XIIIa, green), Cy3 (Ki-67, red), and DAPI (blue) chan-
nels are displayed. Bars, 10 μm. (B) A dot graph shows the percentage of 
Factor XIIIa/ Ki-67 double positive cells among total dermal Factor XIIIa+ 
cells in fi  ve separate donors. In each skin sample, an average of 600 Fac-
tor XIIIa+ cells was analyzed.
Figure 7.  The fate of human dermal DCs after allo-HCT. Nonin-
fl  amed skin samples were obtained from patients who underwent reduced 
intensity (n = 4) or myeloablative conditioning (n = 1) for allo-HCT and 
did not develop GVHD (see Table I) (A–C). GVHD-affected skin samples 
were isolated from four patients who underwent myeloablative condi-
tioning for allo-HCT (see Table II) and developed GVHD (D and E). (A) Cross 
sections of 2-mm skin biopsies obtained 1 mo after allo-HCT were stained 
with X (Cy3) and Y (Cy2) DNA probes, followed by staining with anti-
langerin (Cy3) and HLA-DR (Cy5) antibodies and DAPI as described in 
Materials and methods. A representative image obtained from a female 
recipient injected with male hematopoietic cells is shown. Overlaid images 
of three out of four color channels in indicated combinations (HLA-DR, Y, 
and DAPI on the left, and X, Y, and DAPI on the right) show persistence of 
residual host XX+ HLA-DR+ langerin– cell dermal DCs. Langerin+ cells 
(asterisks) were excluded from the analysis. A female cell (XX; open arrow) 
and a male cell (XY; stealth arrow) are shown. Bars, 10 μm. (B) Dermal DC 
chimerism after allo-HCT in noninfl  amed skin. Dot graphs show the per-
centage of residual host cells among dermal DCs and total BM nucleated 
cells in each patient 30 d after allo-HCT. (C and E) CCL2 is highly up-regu-
lated in GVHD-affected skin. Noninfl  amed skin from patient 1 (Table I) (C) 
and GVHD-affected skin from patient 1 (Table II) (D) were stained with 
anti–human CCL-2 mAb (Cy3). Nuclei were counterstained with DAPI. 
Overlaid images of Cy3 (CCL-2, red) and DAPI (blue) channels are dis-
played. Displayed images represent MCP-1 expression in one out of fi  ve 
samples in each patient group. Bars, 100 μm. (E) Dermal DC chimerism in 
GVHD-affected skin. Dot graph shows the percentage of remaining host 
dermal DCs and BM nucleated cells in patients who developed GVHD. JEM VOL. 203, November 27, 2006  2633
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could not be used for immunostaining. HLA-DR+ endothe-
lial cells, present in infl  amed dermis, were easily excluded 
based on their morphology, expression of Von Willebrand 
antigens, and levels of HLA-DR expression (not depicted). 
Although this technique may present a risk of sampling error, 
it has the major advantage of allowing analyses of dermal DCs 
directly in situ, avoiding the manipulation of small skin bi-
opsy samples in vitro. Four out of fi  ve patients analyzed in 
this study received a nonmyeloablative regimen that included 
total body irradiation (TBI; 2 Gy), antithymocyte globulin 
(ATG), and fl  udarabine as described previously (Table I; ref-
erence 45), whereas one patient received conventional mye-
loablative therapy, including busulfan and cyclophosphamide 
(Table I). All patients received GVHD prophylaxis drugs that 
included cyclosporine and mycophenolate mofetil, and none 
of the patients received systemic or topical steroids. Consis-
tent with our previous report (45), all patients achieved 
>93% myeloid and lymphoid donor BM chimerism by 1 mo 
after transplant. Compared with circulating hematopoietic 
cells, 70–75% of dermal DCs remained of host origin in all 
patients at 30 d after transplant (Fig. 7 B and Table I). These 
results demonstrate that recipient dermal DCs can survive re-
duced intensity conditioning for allo-HCT and persist in the 
skin independently of circulating precursors.
Dermal DC turnover in cutaneous GVHD lesions
We previously demonstrated that in mice, GVHD-like 
UV-induced cutaneous injuries lead to the elimination of 
skin-derived LCs and their replacement by circulating LC 
precursors in a CCR2- and CCR6-dependent manner (24). 
Consistent with these data, the results above showed that 
UV-induced cutaneous injuries eliminate skin-derived der-
mal DCs and induce the secretion of CCR2 ligands required 
for the recruitment of circulating dermal DC precursors and 
the establishment of dermal DC chimerism. To explore 
whether cutaneous GVHD lesions in patients also lead to the 
secretion of CCR2 ligands and dermal DC chimerism, we 
examined the skin of four patients who received sex-mis-
matched allo-HCT and developed cutaneous GVHD lesions 
(Table II). All patients received myeloablative regimen and 
developed GVHD 20–60 d after transplant (Table II). We 
found that the CCR2 ligand CCL2 was barely expressed in 
the skin of patients with no GVHD lesions (Fig. 7 C), whereas 
it was strongly up-regulated in the skin of all patients with 
cutaneous GVHD (Fig. 7 D and not depicted). In addition, 
residual host dermal DCs were absent and fully replaced by 
donor-derived dermal DC precursors in cutaneous GVHD 
lesions (Fig. 7 E), suggesting that infl  ammatory changes in-
duced by cutaneous GVHD lead to the elimination of host 
dermal DCs and the recruitment of donor-derived precur-
sors. Our data in mice showing that CCR2 ligands are 
  required for dermal DC chimerism together with CCL2 up-
regulation in cutaneous GVHD lesions in patients suggest 
that CCL2 may also play a role in the recruitment of donor-
derived circulating dermal DC precursors after allo-HCT, 
thereby facilitating dermal DC chimerism.
DISCUSSION
Our results established that in the absence of cutaneous in-
fl  ammatory injuries, a proportion of DCs renews locally and 
independently of circulating precursors in both mouse and 
human dermis. This was demonstrated in several models. 
First, we discovered that up to 5% of dermal DCs are actively 
cycling in quiescent skin in mice. Second, in parabiotic mice 
with separate organs and shared blood circulation, the major-
ity of dermal DCs failed to equilibrate in recipient mice for 
Table I.  The fate of dermal DCs after allo-HCT in the absence of cutaneous GVHD lesions
Pt. Host/donor Conditioning regimen Date of skin biopsy/time 
after transplant
No. of dermal DCs 
analyzed
% Host dermal 
DCs
% Host BM 
cells
1 F/M TBI/Fludarabine/ATG/MM/ Cyclosporine 30 d 102 73.5 2.4
2 F/M TBI/Fludarabine/ATG/MM/Cyclosporine 30 d 52 78.8 0.4
3 F/M TBI/Fludarabine/ATG/MM/Cyclosporine 30 d 40 75 1
4 M/F TBI/Fludarabine/ATG/MM/Cyclosporine 30 d 46 76.1 7
5 F/M Busufan/Cyclosphosphamide/MM/Cyclosporine 30 d 87 71.3 2.4
F, female; M, male; MM, mycophenolate mofetil; TBI, 2 Gy.
Table II.  The fate of dermal DCs in cutaneous GVHD lesions
Pt. Host/donor Conditioning regimen Diagnosis of GVHD/ time 
after tranplant
Date of skin biopsy/
time after transplant
No. of DCs 
analyzed
%Host dermal 
DCs
%Host
BM cells
1 M/F TBI/Cyclosphosphamide 23 d 40 d 11 0 4
2 M/F TBI/Cyclosphosphamide 30 d 40 d 14 0 0
3 M/F TBI/Cyclosphosphamide 40 d 80 d 42 4.8 0.3
4 F/M TBI/Cyclosphosphamide 60 d 6 mo 21 23.8 1
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up to 6 mo after parabiosis despite the mixing of dermal mac-
rophages and blood leukocytes. Third, in lethally irradiated 
mice reconstituted with congenic BM hematopoietic precur-
sors, a substantial proportion of dermal DCs remained of host 
origin for >12 mo after transplant, whereas the majority 
of dermal macrophages was replaced by donor-circulating 
BM-derived precursors within 4 wk. Consistent with our 
  results in mice, we found that 2–3% of dermal DCs are ac-
tively cycling in human quiescent skin. In addition, in pa-
tients who underwent reduced intensity conditioning for 
allo-HCT, the majority of recipient dermal DCs survived the 
conditioning regimen and remained in the skin despite full 
donor BM chimerism.
Parabiotic mice represent powerful tools to explore the 
physiological turnover of hematopoietic cells. The fact that 
6 mo after parabiosis <20% of dermal DCs were recruited 
from the periphery together with our fi  nding that 2–5% of 
dermal DCs in mice and humans are actively cycling in situ 
establish that local proliferation is critical to the maintenance 
of dermal DC homeostasis in the steady state.
The ability of dermal DCs to proliferate locally is not 
unique to dermal DC populations, as we have also identifi  ed 
cycling LCs in murine (19) and human skin (unpublished 
data) and proliferating DCs have also been detected in mice 
spleen in the steady state (46). We have not been able to 
identify obvious phenotypic diff  erences between locally pro-
liferating and blood-derived dermal DCs. In particular, none 
of these populations expressed early hematopoietic precursor 
markers, including fl  k2+/fl  t347, c-kit (47), CD34 (48), and 
Sca-1 (49; not depicted). Thus, it is possible that all dermal 
DCs have local proliferative properties or that a committed 
dermal DC precursor that has taken up residence in the skin 
controls local dermal DC homeostasis in the steady state. 
Identifi  cation of such a precursor will be the subject of fur-
ther studies in the laboratory.
Our results also show that a subset of dermal DCs sur-
vives lethal dose of irradiation and maintains their prolifera-
tion potential. These fi  ndings recall our earlier observation 
that LCs are entirely maintained by local radio-resistant pro-
liferative precursors (19). In contrast, spleen DCs, although 
able to proliferate locally (46), are eliminated after lethal ir-
radiation (19). Therefore, it is possible that all tissue DC 
populations possess local proliferation properties but that 
only specifi  c environments allow DCs to survive radiation 
injuries. The biological need for local DC proliferation is 
  intriguing. This process may serve to maintain local DC 
homeostasis by providing a way to replace migratory DCs in 
the steady state and to repair locally damaged DCs induced 
by minor injuries. We are currently analyzing whether local 
proliferation properties extend to other DC populations in 
peripheral tissues. Collectively, our results oppose the tradi-
tional view that DCs are nondividing terminally diff  erenti-
ated cells that derive only from circulating committed 
precursors (50, 51) and support the new paradigm that tissue 
DCs have local proliferation properties that control their 
  homeostasis in the steady state.
In contrast to DC homeostasis in noninfl  amed skin, UV-
induced cutaneous injuries lead to the replacement of locally 
proliferating dermal DCs by circulating dermal DC precur-
sors in a CCR2-dependent, CCR6-independent manner. 
These results contrast with our earlier fi  ndings demonstrating 
that both CCR2 and CCR6 were required for LC repopula-
tion in infl  amed skin (19, 24) and extend the role of CCR2 
in the recruitment of leukocytes to infl  amed skin to another 
population of cutaneous DCs. Consistent with our results in 
mice, expression of the CCR2 ligand CCL2 was strongly up-
regulated in human infl  amed skin and correlated with the 
disappearance of locally renewing dermal DCs and their re-
placement with circulating dermal DC precursors. This data 
suggests that CCR2 is also important for dermal DC repopu-
lation in human infl  amed skin.
Recently, we demonstrated that circulating CCR2+, but 
not CCR2−, monocytes migrate to infl  amed skin and give 
rise to LCs in vivo (52). It will be interesting to examine 
whether CCR2+ monocytes are also the precursors for der-
mal DCs in the same setting. A recent study revealed that 
CCR2 regulates monocyte egress from the BM rather than 
regulating its recruitment to infl  amed tissues (43). Consistent 
with this observation, we found that CCR2−/− BM progen-
itors give rise to reduced numbers of blood monocytes 
in vivo compared with CCR2+/+ BM progenitors (not 
  depicted). However, induction of local CCR2 ligand gradi-
ents in murine and human injured skin is intriguing, and the 
transfer of purifi  ed CCR2−/− blood dermal DC precursors 
into WT mice exposed to UV light should help to deter-
mine whether CCR2 also acts at local cutaneous infl  amma-
tory sites.
Recipient DCs have been shown to be critical for the 
  development of GVHD (20–26). Identifi   cation of radio-
  resistant and cycling dermal DCs in the murine dermis and of 
a large subset of remaining recipient dermal DCs in patients’ 
skin after reduced intensity for allo-HCT shown in this study 
suggest that dermal DCs may also participate in the develop-
ment of cutaneous GVHD.
The recent introduction of reduced intensity condition-
ing regimens (53) in clinical transplantation is likely to impact 
tissue DC turnover and increase the pool of residual host 
DCs in several tissues, including tissues like the spleen and 
the liver, where DCs are maintained by radio-sensitive pre-
cursors. A recent study compared the kinetics of LC chime-
rism in patients who received reduced intensity versus full 
intensity conditioning for allo-HCT (54). The reduced in-
tensity regimen used a fl  udarabine and Melphalan combina-
tion (54), a regimen more cytotoxic than the one used in our 
study (45). Results from this study showed that a large pool 
of LCs survived both reduced and full intensity regimen. In 
addition, 40 d after transplant, 65% of LCs were still of host 
origin in patients receiving the reduced intensity regimen, al-
though by day 100, all LCs were of donor origin in both 
groups (54). It is likely that conversion to donor LC chime-
rism correlates with the development of GVHD lesions in 
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Although we still lack suffi   cient perspective on the clini-
cal impact of reduced intensity regimens, some studies have 
reported a delayed onset of acute GVHD in recipients of re-
duced intensity conditioning compared with patients treated 
with full intensity conditioning (55, 56). Our results suggest 
that although reduced intensity conditioning does not lead to 
DC activation to a level suffi   cient to induce donor T cell im-
munity at the time of transplant, residual recipient DCs that 
persist in these patients may still trigger delayed GVHD 
symptoms upon the right activating signal (i.e., infection or 
trauma). Another clinical setting where residual host DCs 
may be particularly relevant is in recipients of donor lympho-
cyte infusion (DLI). Early (or preemptive) DLI is used to im-
prove blood chimerism after reduced intensity stem cell 
transplant (57, 58). These infusions are associated with high 
risk of acute GVHD (57) especially in the recipient of unre-
lated donors (58). Exploring ways to eliminate or reduce the 
pool of residual host DCs is likely to improve GVHD out-
come after DLI.
It is important that DC studies after allo-HCT be per-
formed before the onset of acute GVHD because the priming 
of donor T cells against host tissues would also lead to the 
elimination of recipient DCs, removing any proof of their 
participation in this process (24, 54). We have previously 
shown that although host residual LCs play a role in the de-
velopment of cutaneous GVHD, they are eliminated once 
GVHD develops in the skin (24). In addition, the absence of 
residual host dermal DCs in patients with GVHD lesions 
found in this study together with results showing that large 
numbers of host LCs survive the conditioning regimen for 
allo-HCT but disappear from a patient’s skin 40 d later (54) 
may refl  ect this process of elimination (27, 59).
Whether recipient DCs play a role in the initiation or as 
target of a GVHD reaction remains to be determined. These 
studies are critically needed as they should help to determine 
the need for novel conditioning therapies aimed at reducing 
the pool of residual recipient DCs as a means of improving 
GVHD outcome in clinical transplantation. However, when 
considering the negative impact of residual recipient DCs in 
GVHD, it is critical to keep in mind that these cells are likely 
to participate in the generation of potent antitumor immune 
responses and that their elimination may also reduce the 
graft-versus-tumor eff  ect (60). Thus, it is conceivable that 
therapies targeted to tissues that are most aff  ected by GVHD 
and where persistence of a large pool of residual recipient 
DCs has been demonstrated (i.e., the skin) may help improve 
local tissue damage caused by GVHD without hampering a 
systemic graft-versus-tumor eff  ect. Targeted cutaneous ther-
apies could include the use of UV light (24, 61), antibodies to 
cutaneous DCs, or electron beam therapy (62, 63).
MATERIALS AND METHODS
Animals. 5–8-wk-old WT C57BL/6 mice that express the CD45.2 or 
CD45.1 allele of CD45 were purchased from National Cancer Institute. 
CCR2−/− and CCR6−/− mice on the C57BL/6 background were gener-
ated as described previously (64, 65). C57BL/6 mice lacking CCR2 and 
CCR6 (CCR2−/−CCR6−/−) were generated by crossing CCR2−/− and 
CCR6−/− mice and maintained in our animal facility. Transgenic C57BL/6 
mice expressing an enhanced yellow fl  uorescence protein reporter under 
the control of the CD11c promoter (66) were provided by M. Nussenweig 
(The Rockefeller University, New York, NY). All animal protocols were 
approved by the Mount Sinai Medical Center Institutional Animal Care and 
Use Committee.
Human skin biopsies. To examine the presence of cycling human dermal 
DCs in the steady state, normal human split-thickness skin was obtained from 
the New York Firefi  ghter’s Skin Bank from cadavers within 24 h of death. 
Generally, dermatomes were  300-μm thick, including both epidermis and 
the dermis. To follow the fate of dermal DCs after allo-HCT, fi  ve patients 
who underwent sex-mismatch allo-HCT were included from the BM 
  transplantation clinic affi   liated with the Mount Sinai School of Medicine in 
New York under an institutional review board–approved research protocol. 
All but one patient underwent nonmyeloablative conditioning regimen that 
consisted of rabbit ATG (Atgam; Pharmacia-UpJohn), low dose TBI (2 Gy), 
and fl  udarabine as described previously (45). All patients received a GVHD 
prophylaxis drug that includes cyclosporine (6 mg/kg every 12 h) and oral 
mycophenolate mofetil (15 mg/kg every 12 h; CellCept; reference 45). One 
patient received a myeloablative regimen, including busulfan and cyclophos-
phamide. 2-mm skin biopsies were isolated at day 30 after transplant from the 
posterior iliac crest at the same time as routine BM aspiration to perform BM 
chimerism. Characteristics of these patients are included in Table I. None of 
the patients had clinical and histological signs of cutaneous GVHD. To ana-
lyze the fate of dermal DCs in infl  amed skin after allo-HCT, formalin-fi  xed 
and paraffi   n-embedded biopsies of GVHD-aff  ected skin from patients who 
received myeloablative sex-mismatch allo-HCT were obtained from the de-
partment of pathology at Mount Sinai School of Medicine. The diagnosis 
and scoring of acute GVHD was performed by a dermatopathologist. Char-
acteristics of these patients are included in Table II.
Cell media. Complete medium was prepared with RPMI (Cellgro), sup-
plemented with 10% FBS (Sigma-Aldrich) and 1× penicillin/streptomycin 
(Cellgro). Staining of cell suspensions was done in PBS with 1% FBS and 
2 mM EDTA.
Parabiosis. Parabiotic mice were generated as described previously (67). 
Each pair of parabiotic mice consisted of a WT and a GFP-transgenic mouse 
on a C57BL/6 background. At 6 mo after initiation of parabiosis, mice were 
killed and subjected to tissue analysis. To confi  rm effi   cient blood mixing in 
parabiotic mice, the percentage of GFP+ and GFP– cells among blood 
CD45+ leukocytes was analyzed in each animal.
Preparation of dermal cell suspension. Mouse ears were split in two 
(dorsal and ventral) parts and incubated for 45 min in PBS containing 0.5% 
trypsin with 5 mM EDTA (Invitrogen) to allow for separation of dermal and 
epidermal sheets. Dermal sheets were then cut in small pieces and incubated for 
2.5 h in collagenase (Worthington) to obtain dermal cell suspension.
Flow cytometry. mAbs against mouse I-Ab (clone AF6-120.1), CD11c 
(clone HL3), CD45 (clone 30-F11), CD45.1 (clone A2), CD45.2 (clone 
104), CD86 (clone GL1), CD54 (clone 3E2), Gr-1 (Ly6C, clone 1A8), Gr-1 
(Ly6C/G, clone RB6-8C5), DC-SIGN (clone 5H10), CD3 (clone 17A2), 
corresponding isotype controls, and secondary reagents (PE-Cy7–  conjugated 
streptavidin) were purchased from BD Biosciences. mAbs against CD11b 
(clone M1/70), CD115 (clone AFS9), B220 (clone RA3-682), CD4 (clone 
L3T4), and CD8α (clone 53-6.7) were obtained from eBioscience. F480 
(clone C1:A3-1) and CD205 (clone NLDC145) were purchased from Sero-
tech. Anti-langerin antibody (goat polyclonal IgG) was purchased from Santa 
Cruz Biotechnology, Inc. Intracellular staining against langerin was per-
formed with the BD Cytofi  x/Cytoperm kit (BD Biosciences) according to 
the manufacturer’s protocol. Multi-parameter analyses of stained cell suspen-
sions were performed on an LSR II (Becton Dickinson) and analyzed with 
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Allogeneic BM transplantation in mice. 8-wk-old CD45.2+ C57BL/6 
mice were lethally irradiated with 1,200 rad delivered in two doses of 600 
rad each, 3 h apart, and injected i.v. with 5 × 105 BM cells obtained from 
congenic CD45.1+ C57BL/6 adult mice. To address the role of CCR2 and 
CCR6 in dermal DC repopulation in injured skin, lethally irradiated 
CD45.1+ mice were reconstituted with mixed BM cells that consisted of a 
1:1 mixture of WT CD45.1+ BM cells and CD45.2+ BM isolated from WT, 
CCR2−/−, CCR6−/−, or CCR2/CCR6−/− mutant mice. Levels of blood 
donor chimerism were analyzed by measuring the percentage of CD45.1+ 
cells among total B220+ B cells, Ly6C/G+ CD115– granulocytes, and 
CD115+ monocytes in the blood 3 wk after transplantation.
Induction of cutaneous injury in BM chimeric mice. Lethally irradi-
ated mice were reconstituted with congenic BM cells and analyzed for blood 
donor chimerism 3 wk later. Fully donor BM chimeric mice were then ex-
posed to UV light as described previously (19). Mouse ears were collected 
before and at various time points after UV exposure. When mentioned, back 
skin was also shaved and exposed to UV light.
BrdU labeling in vivo. 4 wk after transplantation, (CD45.1+ BM®CD45.2+ 
recipient) chimeric mice were injected i.p. with 1 mg BrdU (Sigma-Aldrich), 
to ensure its immediate availability, and given BrdU in 0.4 mg/ml of sterile 
drinking water that was changed daily for 3 wk. Dermal cell suspensions were 
prepared at diff  erent time points after initial BrdU administration. The per-
centage of BrdU+ cells among host (CD45.2+) and donor (CD45.1+) dermal 
DCs was analyzed using the BrdU Flow kit (BD Biosciences) according to 
the manufacturer’s protocol.
Immunofl  uorescence analysis of murine skin. For murine skin analysis, 
8-μm histological sections of snap-frozen back skin were fi  xed in 100% ace-
tone for 10 min and rinsed in PBS. Tissue sections were then stained with 
anti-langerin (goat IgG) and anti-CD11c (Armenian hamster IgG) antibodies 
for 1 h, washed in PBS, and incubated with secondary reagents Cy2-conju-
gated anti–goat IgG and biotinylated anti–hamster IgG followed by streptav-
idin-Cy3. To analyze local cell proliferation, tissue sections were stained 
with anti-langerin or CD11c antibody and costained with anti–mouse Ki-67 
antibody (rat IgG, clone TEC-3; DakoCytomation), followed by Cy3 anti–
rat IgG together with biotinylated anti–goat or anti–hamster IgG and com-
pleted by streptavidin-Cy2. To analyze CCL2 expression, slides were 
incubated with anti-murine CCL2 antibody (goat IgG; R&D Systems), fol-
lowed by Cy3 anti–goat IgG. All secondary reagents were purchased from 
Jackson ImmunoResearch Laboratories.
Immunofl  uorescence analysis of human skin. Human skin samples 
were fi  xed in 10% buff  ered formalin and embedded in paraffi   n. 6-μm skin 
cross sections were subjected to antigen retrieval using the antigen un-
masking solution (Vector Laboratories). Tissue sections were stained with 
anti–human Factor XIIIa (mouse IgG; Vector Laboratories) and anti–
  human Ki-67 (rabbit IgG; Vector Laboratories) antibodies for 1 h, washed, 
and incubated with Cy2 anti–mouse IgG and biotinylated anti–rabbit IgG, 
followed by streptavidin-Cy3. Staining for CCL2 was performed using 
anti–human CCL2 antibody (mouse IgG, clone 24822.11; Sigma- Aldrich), 
followed by Cy3 anti–mouse IgG. Stainings with isotype controls 
were always performed in parallel. After completing the staining, slides 
were mounted with DAPI-containing Vectashield mounting medium 
(Vector Laboratories).
Fluorescence microscopy. Low magnifi  cation images (20×) were ac-
quired using a Leica DMRA2 fl  uorescence microscope with a Hamamatsu 
CCD digital camera and analyzed using Openlab software (Improvision). 
High magnifi  cation multicolored images (40 and 60×) were obtained with 
a confi  gured for fl  uorescence imaging microscope (BX61WI; Olympus). 
Images were collected with a Coolsnap camera. A Dell workstation with 
SlideBook software (Intelligent Imaging Innovations) provided the synchro-
nization of components, data acquisition, and image analysis.
Dual FISH and immunofl  uorescence analysis to determine dermal 
DC chimerism in patients after sex-mismatched allo-HCT. 2-mm 
skin biopsies were isolated from patients at the indicated time after transplant, 
fi   xed in formalin overnight, and embedded in paraffi   n.  6-μm paraffi   n-
embedded skin sections were deparaffi   nized and antigen retrieval was per-
formed by incubating slides in 1× sodium citrate buff  er (Antigen Retrieval 
Solution; Vector Laboratories) for 16 min at 100°C. Slides were then washed 
three times in distilled water and incubated in 2× saline sodium citrate buff  er 
(Vysis Inc.) for 30 min at 37°C. To expose genomic DNA, slides were 
treated with 0.5 mg/ml pepsin (Sigma-Aldrich) in 0.1 N HCl for 30 min at 
37°C and washed in 2× saline sodium citrate buff  er at room temperature for 
10 min. After dehydration in ethanol, slides were dried out and subjected to 
FISH. X and Y chromosome–specifi  c DNA probes provided in hybridiza-
tion buff  er (Vysis Inc.) were applied to the slides. Tissue DNA was denatured 
for 10 min at 72°C, followed by hybridization at 42°C overnight. Next, 
slides were washed in 0.4× saline sodium citrate at 73°C for 2 min, 0.1% of 
NP-40 in 2× saline sodium citrate for 1 min at room temperature, and in 2× 
saline sodium citrate for 5 min at room temperature. Slides were then stained 
with HLA-DR and anti-langerin antibody as described in Results, washed 
extensively in PBS, and mounted with DAPI-containing Vectashield mount-
ing medium. Tissue sections were analyzed with a microscope (BX61WI; 
Olympus). Four fi  lter sets were simultaneously used to picture each skin sec-
tion in a Z-stack mode. Although we always acquired four diff  erent immu-
nostainings, the available software only allowed the display of three separate 
color sets. HLA-DR+ (Cy5) langerin– (Cy3) dermal cells were analyzed 
for the presence of X- or Y-specifi  c probes inside of their DAPI-stained nu-
clei. Only cells containing two dots were acquired for the statistical analysis. 
Normal skin biopsies of male and female origin were used as controls.
Analysis of BM chimerism in patients after allo-HCT. BM chimerism 
was analyzed by interphase FISH using dual color XY probes as described 
previously (68). In brief, an aliquot of BM cells was applied on slides pre-
pared for DNA hybridization with a dual X/Y probe mixed with hybridiza-
tion buff  er. The target and probe DNA was denatured for 10 min at 72°C, 
followed by hybridization at 42°C overnight. The slides were washed, dehy-
drated, and mounted the next day. Interphase nuclei were counterstained 
with DAPI, and the expression of X and Y chromosomes on DAPI+ nuclei 
was evaluated with a Zeiss Axioplan microscope. Only nuclei with two sig-
nals (XX or XY) were calculated. The percent chimerism was evaluated by 
two observers, each scoring 150 nuclei. At least six images were taken for 
documenting each hybridization signal pattern. To determine the accuracy 
and sensitivity of the probe hybridization, data were also obtained from male 
and female controls.
Statistical analysis. Data are presented as mean ± standard deviation. The 
statistical signifi  cance of diff  erences between group means was determined 
with the Student’s t test. p-values of <0.05 were considered signifi  cant.
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